Senior Director of Clinical Quality Assurance
4D Molecular Therapeutics
Senior Director of Clinical Quality Assurance
4D Molecular Therapeutics
Develops gene therapies using AAV vectors
Attention recruitment agencies: All agency inquiries are vetted through 4DMT’s internal Talent Acquisition team. No unsolicited resumes will be accepted. The 4DMT Talent Acquisition team must expressly engage agencies on any requisition. Agencies contacting hiring managers directly will not be tolerated, and doing so may impact your ability to work with 4DMT in the future.
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration and the second indication is diabetic macular edema, which are both in Phase 3 development. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery.
We are taking genetic medicine to new heights and into new disease areas to overcome challenges not addressed by existing medicines. This incredible challenge drives our relentless and talented team. Our people are the essence of our inspiring, innovative and collaborative environment that encourages individual contributions and provides opportunities for career development. We seek the best in the industry who identify with our mission and our bold and innovative results-driven approach. Our Core Values drive the way we work together:
Join us in creating the future of genetic medicine.
GENERAL SUMMARY
The Senior Director of Clinical Quality Assurance (CQA) will provide strategic and operational Quality Assurance leadership and oversight for multiple, registrational, global 4DMT-sponsored clinical trials, ensuring trials are executed in compliance with applicable international regulatory requirements for Good Clinical Practice (GCP).
This position reports to the Executive Director, Quality Assurance and is accountable for advancing the CQA mission, objectives, and strategic plan through proactive quality strategy, risk-based oversight, inspection readiness, and continuous improvement of clinical quality systems.
MAJOR DUTIES & RESPONSIBILITIES:
Provide strategic Quality leadership and oversight for multiple 4DMT Clinical Studies, including the following study-specific activities:
Lead and/or provide oversight for investigation and management of significant Clinical Study Quality Events:
Champion and advance a culture of quality that fosters learning, respect, open communication, collaboration, integration, and teamwork:
Lead preparedness / readiness / management of BIMO / GCP inspections:
QUALIFICATIONS:
Education:
Experience:
Other Qualifications/Skills:
Travel: %5
Physical Requirements and Working Conditions:
Base salary compensation range: $245,000 - 286,000
Please note, the base salary compensation range and actual salary offered to the final candidate depends on various factors: candidate’s geographical location, relevant work experience, skills, and years of experience.
Develops gene therapies using AAV vectors
4D Molecular Therapeutics develops gene therapies using its Therapeutic Vector Evolution platform to create adeno-associated virus (AAV) delivery vectors that transport therapeutic genes to patients’ cells. This clinical-stage biotech focuses on genetic diseases such as cystic fibrosis, delivering genetic material through engineered AAV vectors in targeted tissues. Its product approach involves R&D and clinical trials to test safety and efficacy, followed by commercialization through direct sales or partnerships with larger pharmaceutical companies. The company differentiates itself with a proprietary vector evolution technology that enables tailored, precise gene delivery and by pursuing funding and collaborations (e.g., with the Cystic Fibrosis Foundation) to advance therapies like 4D-710. The goal is to bring gene therapies to market to treat serious genetic diseases and improve patient outcomes, funded by equity investments, strategic partnerships, and future product sales.
Explore more opportunities at 4D Molecular Therapeutics